Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06590454 · ClinicalTrials.gov registry record · Phase 2
REVerse Intestinal Metaplasia in the Stomach (REVISE)
A Phase 2 study of Gastric Intestinal Metaplasia and Gastric Precancer, sponsored by Katherine Garman.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 32
- Enrollment target
- 1
- Study location
NCT06590454: Recruiting Phase 2 study of Gastric Intestinal Metaplasia and Gastric Precancer, sponsored by Katherine Garman.
NCT06590454 is a Phase 2 study of Gastric Intestinal Metaplasia and Gastric Precancer that is actively recruiting participants, run by Katherine Garman. The registered enrollment target is 32 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (76% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06590454, a Phase 2 study of Gastric Intestinal Metaplasia and Gastric Precancer, is actively recruiting participants, sponsored by Katherine Garman.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 32 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is designed to test the use of Pyrvinium vs placebo as a treatment for gastric intestinal metaplasia with features associated with increased risk of cancer. Response will be determined by assessing the extent and quality of the gastric intestinal metaplasia before and after treatment. A secondary aim will be to generate gastric organoids from patient-derived samples to test the effects of pyrvinium in vitro in patient-derived samples, and also to identify new drugs that may help reverse gastric intestinal metaplasia.
Primary Outcome
For the efficacy analysis, the investigators will primarily evaluate the change in the number of clinical biopsies with evidence of gastric intestinal metaplasia from the screening endoscopy to the follow-up endoscopy.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Pyrvinium
Study Locations (1)
North Carolina
- Duke Health - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2025-12-15 |
| Est. Completion | 2026-10-01 |
| Phase | Phase 2 |
What NCT06590454 shows while recruiting
NCT06590454 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 32 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (76% lower).
The record links to 2 conditions, with Gastric Intestinal Metaplasia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06590454 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT06590454 about?
NCT06590454 is a clinical study titled "REVerse Intestinal Metaplasia in the Stomach (REVISE)". This study is designed to test the use of Pyrvinium vs placebo as a treatment for gastric intestinal metaplasia with features associated with increased risk of cancer. Response will be determined by assessing the extent and quality of the gastric intestinal metaplasia before and after treatment. A ...
What is the current status of trial NCT06590454?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 32 participants. The study started on 2025-12-15. Estimated completion is 2026-10-01.
What conditions does trial NCT06590454 study?
This clinical trial studies the following conditions: Gastric Intestinal Metaplasia, Gastric Precancer.
What interventions are being tested in trial NCT06590454?
The interventions under investigation include: Placebo (DRUG), Pyrvinium (DRUG).
Who is sponsoring clinical trial NCT06590454?
This trial is sponsored by Katherine Garman, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06590454 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gastric Intestinal Metaplasia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06590454's enrollment target sits among peer trials
32 1563rd of 2000 higher than 424 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02445781 · 32 participants · Early Phase 1
Differing Levels of Hypoglycemia
- NCT02792270 · 32 participants · NA
Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT
- NCT03068910 · 32 participants · Early Phase 1
Hyperandrogenemia and Altered Day-night LH Pulse Patterns
- NCT03208868 · 32 participants · NA
Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI